Valuation: Egetis Therapeutics AB

Market Cap 5.21B 517M 469M 434M 391M 737M 48.77B 763M 2.06B 26.05B 1.94B 1.9B 82.69B P/E 2026 *
132x
P/E 2027 * -43.3x
Enterprise Value 4.28B 425M 385M 356M 321M 605M 40.04B 627M 1.7B 21.39B 1.59B 1.56B 67.89B EV / Sales 2026 *
37.9x
EV / Sales 2027 * 8.77x
Free-Float
37.69%
Yield 2026 *
-
Yield 2027 * -
1 day-0.62%
Current month+10.54%
1 month+20.35%
3 months+56.84%
6 months+65.48%
Current year+108.24%
1 week 11.1
Extreme 11.1
11.2
1 month 8.96
Extreme 8.96
11.2
Current year 4.23
Extreme 4.23
11.2
1 year 3.62
Extreme 3.625
11.2
3 years 3.02
Extreme 3.025
11.2
5 years 3
Extreme 3.005
11.2
10 years 3
Extreme 3.005
22.6
Manager TitleAgeSince
Chief Executive Officer 50 16/06/2017
Director of Finance/CFO 47 31/12/2017
Chief Tech/Sci/R&D Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2017
Chairman 61 06/05/2024
Director/Board Member 63 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Sell

Executive/Senior Manager

-594 0.0001%
8/31/26 A Exercice

Chief Financial Officer

1,099 0.0002%
8/31/26 A Buy

Chief Operating Officer

1,099 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%0.00%+89.44%+126.25% 517M
-2.69%-0.48%+53.97%+66.82% 66.33B
+0.18%+3.09%+11.08%+95.60% 60.62B
+1.11%+2.03%+24.73%+90.43% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
+3.03%-3.17%+79.45%+61.43% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average +0.14%+0.12%+42.43%+172.39% 41B
Weighted average by Cap. -0.09%+0.20%+37.02%+153.10%

Financials

2026 *2027 *
Net sales 113M 11.22M 10.17M 9.4M 8.48M 15.99M 1.06B 16.55M 44.79M 565M 42.1M 41.2M 1.79B 512M 50.85M 46.08M 42.62M 38.45M 72.47M 4.79B 75.02M 203M 2.56B 191M 187M 8.13B
Net income 414M 41.12M 37.26M 34.46M 31.09M 58.6M 3.88B 60.66M 164M 2.07B 154M 151M 6.57B -42.62M -4.23M -3.84M -3.55M -3.2M -6.03M -399M -6.25M -16.9M -213M -15.88M -15.55M -677M
Net Debt -932M -92.56M -83.88M -77.58M -70M -132M -8.73B -137M -370M -4.66B -347M -340M -14.8B -720M -71.51M -64.81M -59.94M -54.08M -102M -6.74B -106M -286M -3.6B -268M -263M -11.43B
Projected Income Statement - Annual - Egetis Therapeutics AB
Logo Egetis Therapeutics AB
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Employees
61
Date Price Change Volume
16/11/26 SEK 11.12 -0.71% 844,215
13/11/26 SEK 11.20 +0.72% 2,237,972
12/11/26 SEK 11.12 0.00% 2,578,051
11/11/26 SEK 11.12 +0.18% 5,182,684
10/11/26 SEK 11.10 -0.18% 4,722,428
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Egetis Therapeutics AB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
11.20SEK
Average target price
11.21SEK
Spread / Average Target
+0.11%
  1. Stock Market
  2. Stocks
  3. EGTX Stock